⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TRDA News
Entrada Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
TRDA
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
globenewswire.com
TRDA
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
globenewswire.com
TRDA
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
globenewswire.com
TRDA
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
TRDA
Form 8-K
sec.gov
TRDA
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
globenewswire.com
TRDA
Form 8-K
sec.gov
TRDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
accessnewswire.com
TRDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
accessnewswire.com
TRDA